
TY  - JOUR
TI  - XLIV ESAO and VII IFAO Congress, 6-9 September 2017, Vienna, Austria
JO  - Artificial Organs
JA  - Artificial Organs
VL  - 41
IS  - 9
SN  - 0160-564X
UR  - https://doi.org/10.1111/aor.13019
DO  - doi:10.1111/aor.13019
SP  - A1
EP  - A81
PY  - 2017
ER  - 

TY  - JOUR
TI  - Category Index
JO  - Hepatology
JA  - Hepatology
VL  - 68
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.30259
DO  - doi:10.1002/hep.30259
SP  - 1431
EP  - 1443
PY  - 2018
ER  - 

TY  - JOUR
TI  - ABSTRACTS – Online Panel Discussion (i-Pos)
JO  - International Journal of Rheumatic Diseases
VL  - 11
IS  - s1
SN  - 1756-1841
UR  - https://doi.org/10.1111/j.1479-8077.2008.00373.x
DO  - doi:10.1111/j.1479-8077.2008.00373.x
SP  - A84
EP  - A514
PY  - 2008
ER  - 

TY  - JOUR
TI  - POSTER SESSION: CLINICAL
JO  - European Journal of Heart Failure
JA  - European Journal of Heart Failure
VL  - 12
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1093/eurjhf/hst009
DO  - doi:10.1093/eurjhf/hst009
SP  - S73
EP  - S325
PY  - 2013
ER  - 

TY  - JOUR
AU  - SCHELLER, E. L.
AU  - KREBSBACH, P. H.
AU  - KOHN, D. H.
TI  - Tissue engineering: state of the art in oral rehabilitation
JO  - Journal of Oral Rehabilitation
VL  - 36
IS  - 5
SN  - 0305-182X
UR  - https://doi.org/10.1111/j.1365-2842.2009.01939.x
DO  - doi:10.1111/j.1365-2842.2009.01939.x
SP  - 368
EP  - 389
KW  - biomaterials
KW  - design
KW  - cell recognition
KW  - teeth
KW  - oral mucosa
KW  - salivary gland
KW  - bone
KW  - periodontium
PY  - 2009
AB  - Summary? More than 85% of the global population requires repair or replacement of a craniofacial structure. These defects range from simple tooth decay to radical oncologic craniofacial resection. Regeneration of oral and craniofacial tissues presents a formidable challenge that requires synthesis of basic science, clinical science and engineering technology. Identification of appropriate scaffolds, cell sources and spatial and temporal signals (the tissue engineering triad) is necessary to optimize development of a single tissue, hybrid organ or interface. Furthermore, combining the understanding of the interactions between molecules of the extracellular matrix and attached cells with an understanding of the gene expression needed to induce differentiation and tissue growth will provide the design basis for translating basic science into rationally developed components of this tissue engineering triad. Dental tissue engineers are interested in regeneration of teeth, oral mucosa, salivary glands, bone and periodontium. Many of these oral structures are hybrid tissues. For example, engineering the periodontium requires growth of alveolar bone, cementum and the periodontal ligament. Recapitulation of biological development of hybrid tissues and interfaces presents a challenge that exceeds that of engineering just a single tissue. Advances made in dental interface engineering will allow these tissues to serve as model systems for engineering other tissues or organs of the body. This review will begin by covering basic tissue engineering principles and strategic design of functional biomaterials. We will then explore the impact of biomaterials design on the status of craniofacial tissue engineering and current challenges and opportunities in dental tissue engineering.
ER  - 

TY  - JOUR
TI  - 2000 Annual Meeting Abstracts
JO  - Journal of Periodontology
JA  - Journal of Periodontology
VL  - 71
IS  - 12
SN  - 0022-3492
UR  - https://doi.org/10.1902/jop.2000.71.12.1910
DO  - doi:10.1902/jop.2000.71.12.1910
SP  - 1910
EP  - 1927
PY  - 2000
ER  - 

TY  - JOUR
TI  - Poster Abstracts  Others—Published Only
JO  - Respirology
VL  - 10
IS  - s3
SN  - 1323-7799
UR  - https://doi.org/10.1111/j.1440-1843.2005.00775.x
DO  - doi:10.1111/j.1440-1843.2005.00775.x
SP  - A108
EP  - A208
PY  - 2005
ER  - 

TY  - JOUR
TI  - Non- Moderated Posters
JO  - BJU International
VL  - 94
IS  - s2
SN  - 1464-4096
UR  - https://doi.org/10.1111/j.1465-5101.2004.05080.x
DO  - doi:10.1111/j.1465-5101.2004.05080.x
SP  - 163
EP  - 309
PY  - 2004
ER  - 

TY  - JOUR
C7  - e10257
TI  - Abstracts from the Bone and Muscle Interactions: The Mechanical and Beyond Meeting August 2019
JO  - JBMR Plus
JA  - JBMR Plus
VL  - 3
IS  - S4
SN  - 2475-0328
UR  - https://doi.org/10.1002/jbm4.10257
DO  - doi:10.1002/jbm4.10257
SP  - e10257
PY  - 2019
ER  - 

TY  - JOUR
TI  - 10th Annual meeting of French Society of Pharmacology, 73rd Annual meeting of Society of Physiology, 27th pharmacovigilance meeting, 54th APNET Seminar and 4th CHU CIC meeting (Corum Montpellier 10-12 April 2006)
JO  - Fundamental & Clinical Pharmacology
VL  - 20
IS  - 2
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2006.00409.x
DO  - doi:10.1111/j.1472-8206.2006.00409.x
SP  - 145
EP  - 234
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts 544 - 1089
JO  - American Journal of Transplantation
VL  - 4
IS  - s8
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6135.2004.0480b.x
DO  - doi:10.1111/j.1600-6135.2004.0480b.x
SP  - 308
EP  - 456
PY  - 2004
ER  - 

TY  - JOUR
TI  - Tentative Schedule of Abstract Presentations, April 28 to May 1, 2007, Tampa Convention Center
JO  - Wound Repair and Regeneration
VL  - 15
IS  - 2
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2007.00217.x
DO  - doi:10.1111/j.1524-475X.2007.00217.x
SP  - A13
EP  - A54
PY  - 2007
ER  - 

TY  - JOUR
AU  - Tarroni, Paola
AU  - Villa, Isabella
AU  - Mrak, Emanuela
AU  - Zolezzi, Francesca
AU  - Mattioli, Michela
AU  - Gattuso, Claudio
AU  - Rubinacci, Alessandro
TI  - Microarray analysis of 1,25(OH)2D3 regulated gene expression in human primary osteoblasts
JO  - Journal of Cellular Biochemistry
JA  - J. Cell. Biochem.
VL  - 113
IS  - 2
SN  - 0730-2312
UR  - https://doi.org/10.1002/jcb.23392
DO  - doi:10.1002/jcb.23392
SP  - 640
EP  - 649
KW  - 1,25(OH)2D3
KW  - HUMAN PRIMARY OSTEOBLASTS
KW  - TRANSCRIPTIONAL PROFILING
KW  - MICROARRAY
PY  - 2012
AB  - Abstract Though extensive studies have been conducted, questions regarding the molecular effectors and pathways underlying the regulatory role of 1,25(OH)2D3 in human osteoblasts other than cell differentiation and matrix protein production remain unanswered. This study aims to identify genes and pathways that are modulated by 1,25(OH)2D3 treatment in human osteoblasts. Primary osteoblast cultures obtained from human bone tissue samples were treated with 1,25(OH)2D3 (10?7?M) for 24?h and their transcritptomes were profiled by microarray analysis using the Affymetrix GeneChip?. Statistical analysis was conducted to identify genes whose expression is significantly modulated following 1,25(OH)2D3 treatment. One hundred and fifty-eight genes were found to be differentially expressed. Of these, 136 were upregulated, indicating clear transcriptional activation by 1,25(OH)2D3. Biostatistical evaluation of microarray data by Ingenuity Pathways Analysis (IPA) revealed a relevant modulation of genes involved in vitamin D metabolism (CYP24), immune functions (CD14), neurotransmitter transporters (SLC1A1, SLC22A3), and coagulation [thrombomodulin (THBD), tissue plasminogen activator (PLAT), endothelial protein C receptor (PROCR), thrombin receptor (F2R)]. We identified a restricted number of highly regulated genes and confirmed their differential expression by real-time quantitative PCR (RT qPCR). The present genome-wide microarray analysis on 1,25(OH)2D3-treated human osteoblasts reveals an interplay of critical regulatory and metabolic pathways and supports the hypothesis that 1,25(OH)2D3 can modulate the coagulation process through osteoblasts, activates osteoclastogenesis through inflammation signaling, modulates the effects of monoamines by affecting their reuptake. J. Cell. Biochem. 113: 640?649, 2012. ? 2011 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
TI  - Acute coronary syndromes, myocardial infarction, thrombectomy and vulnerable plaque
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 87
IS  - S2
SN  - 1522-1946
UR  - https://doi.org/10.1002/ccd.26513
DO  - doi:10.1002/ccd.26513
SP  - S1
EP  - S169
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Haemophilia
JA  - Haemophilia
VL  - 20
IS  - s3
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.12400
DO  - doi:10.1111/hae.12400
SP  - 1
EP  - 186
PY  - 2014
ER  - 

TY  - JOUR
AU  - Aronica, Eleonora
AU  - Bauer, Sebastian
AU  - Bozzi, Yuri
AU  - Caleo, Matteo
AU  - Dingledine, Raymond
AU  - Gorter, Jan A.
AU  - Henshall, David C.
AU  - Kaufer, Daniela
AU  - Koh, Sookyong
AU  - Löscher, Wolfgang
AU  - Louboutin, Jean-Pierre
AU  - Mishto, Michele
AU  - Norwood, Braxton A.
AU  - Palma, Eleonora
AU  - Poulter, Michael O.
AU  - Terrone, Gaetano
AU  - Vezzani, Annamaria
AU  - Kaminski, Rafal M.
TI  - Neuroinflammatory targets and treatments for epilepsy validated in experimental models
JO  - Epilepsia
JA  - Epilepsia
VL  - 58
IS  - S3
SN  - 0013-9580
UR  - https://doi.org/10.1111/epi.13783
DO  - doi:10.1111/epi.13783
SP  - 27
EP  - 38
KW  - Inflammation
KW  - Immune response
KW  - Drug development
KW  - Anti-ictogenesis
KW  - Antiepileptogenesis
KW  - Disease modification
KW  - Epilepsy
PY  - 2017
AB  - Summary A large body of evidence that has accumulated over the past decade strongly supports the role of inflammation in the pathophysiology of human epilepsy. Specific inflammatory molecules and pathways have been identified that influence various pathologic outcomes in different experimental models of epilepsy. Most importantly, the same inflammatory pathways have also been found in surgically resected brain tissue from patients with treatment-resistant epilepsy. New antiseizure therapies may be derived from these novel potential targets. An essential and crucial question is whether targeting these molecules and pathways may result in anti-ictogenesis, antiepileptogenesis, and/or disease-modification effects. Therefore, preclinical testing in models mimicking relevant aspects of epileptogenesis is needed to guide integrated experimental and clinical trial designs. We discuss the most recent preclinical proof-of-concept studies validating a number of therapeutic approaches against inflammatory mechanisms in animal models that could represent novel avenues for drug development in epilepsy. Finally, we suggest future directions to accelerate preclinical to clinical translation of these recent discoveries.
ER  - 

TY  - JOUR
TI  - American Transplant Congress 2007 Executive and Program Planning Committees and Abstract Review Committees
JO  - American Journal of Transplantation
VL  - 7
IS  - s2
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6143.2007.01811.x
DO  - doi:10.1111/j.1600-6143.2007.01811.x
SP  - 17
EP  - 584
PY  - 2007
ER  - 

TY  - JOUR
TI  - Inflammation, growth regulatory molecules & atherosclerosis
JO  - Journal of Cellular Biochemistry
JA  - J. Cell. Biochem.
VL  - 56
IS  - S18A
SN  - 0730-2312
UR  - https://doi.org/10.1002/jcb.240560509
DO  - doi:10.1002/jcb.240560509
SP  - 256
EP  - 303
PY  - 1994
ER  - 

TY  - JOUR
TI  - Program
JO  - International Journal of Urology
JA  - Int. J. Urol.
VL  - 25
IS  - S1
SN  - 0919-8172
UR  - https://doi.org/10.1111/iju.13771
DO  - doi:10.1111/iju.13771
SP  - 27
EP  - 78
PY  - 2018
ER  - 

TY  - JOUR
TI  - Keyword Index
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 60
IS  - s4
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2012.04002.x
DO  - doi:10.1111/j.1532-5415.2012.04002.x
SP  - S264
EP  - S273
PY  - 2012
ER  - 
